Improved Risk Stratification of MDS Patients With IPSS-M: A Single-Institution Experience

被引：0
|
作者：
Kurt, Habibe [1 ,2 ]
Chergui, Adel [3 ,4 ]
Omer, Mohamed [3 ,4 ]
Reagan, John L. [3 ,4 ]
Olszewski, Adam J. [3 ,4 ]
机构：
[1] Brigham & Womens Hosp, Boston, MA USA
[2] Harvard Univ, Boston, MA USA
[3] Lifespan Canc Inst, Providence, RI USA
[4] Brown Univ, Providence, RI USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
MDS; risk stratification; IPSS-R; IPSS-M;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MDS-663
引用
收藏
页码：S402 / S402
页数：1
相关论文
共 50 条
  • [1] IPSS-M Improves the Risk Stratification of MDS Patients: A Single Institution Experience
    Omer, Mohamed
    Olszewski, Adam
    Kurt, Habibe
    LABORATORY INVESTIGATION, 2023, 103 (03) : S1215 - S1216
  • [2] Risk prediction in MDS: independent validation of the IPSS-M—ready for routine?
    Constance Baer
    Sandra Huber
    Stephan Hutter
    Manja Meggendorfer
    Niroshan Nadarajah
    Wencke Walter
    Uwe Platzbecker
    Katharina S. Götze
    Wolfgang Kern
    Torsten Haferlach
    Gregor Hoermann
    Claudia Haferlach
    Leukemia, 2023, 37 : 938 - 941
  • [3] A Retrospective Validation Study Comparing the IPSS-M and IPSS-R Risk Stratification Scores in Primary and Secondary Myelodysplastic Syndrome (MDS)
    Sabile, Jean M. G.
    Kaempf, Andy
    Tomic, Kaitlyn
    Manu, Gurusidda
    Swords, Ronan T.
    Migdady, Yazan
    BLOOD, 2022, 140 : 4088 - 4089
  • [4] IPSS-M Is More Powerful for MDS Patients Older Than 60 Years Old
    Wu, Junying
    Zhang, Yudi
    Qin, Tiejun
    Xu, Zefeng
    Qu, Shiqiang
    Pan, Lijuan
    Li, Bing
    Gao, Qingyan
    Gale, Robert Peter
    Xiao, Zhijian
    BLOOD, 2022, 140 : 4092 - 4093
  • [5] Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC
    Huber, Sandra
    Baer, Constance
    Hutter, Stephan
    Dicker, Frank
    Fuhrmann, Irene
    Meggendorfer, Manja
    Pohlkamp, Christian
    Kern, Wolfgang
    Haferlach, Torsten
    Haferlach, Claudia
    Hoermann, Gregor
    LEUKEMIA, 2023, 37 (10) : 2138 - 2141
  • [6] Risk Prediction in MDS: A Validation of the IPSS-M and Comparison to IPSS-R and to Two Other Personalized Prediction Tools
    Baer, Constance
    Huber, Sandra
    Hutter, Stephan
    Meggendorfer, Manja
    Nadarajah, Niroshan
    Walter, Wencke
    Platzbecker, Uwe
    Gotze, Katharina
    Kern, Wolfgang
    Haferlach, Torsten
    Hoermann, Gregor
    Haferlach, Claudia
    BLOOD, 2022, 140 : 1128 - 1129
  • [7] Reality check of IPSS-M - prospective analysis of 171 real-world MDS patients
    Baer, C.
    Hutter, S.
    Summerer, I.
    Huber, S.
    Hoermann, G.
    Kern, W.
    Meggendorfer, M.
    Haferlach, T.
    Haferlach, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 201 - 202
  • [8] Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC
    Sandra Huber
    Constance Baer
    Stephan Hutter
    Frank Dicker
    Irene Fuhrmann
    Manja Meggendorfer
    Christian Pohlkamp
    Wolfgang Kern
    Torsten Haferlach
    Claudia Haferlach
    Gregor Hoermann
    Leukemia, 2023, 37 : 2138 - 2141
  • [9] Genomic Landscape of Ccus Compared to MDS Indicates a Potential Applicability of the IPSS-M
    Huber, Sandra
    Baer, Constance Regina
    Hutter, Stephan
    Hoermann, Gregor
    Pohlkamp, Christian
    Walter, Wencke
    Meggendorfer, Manja
    Kern, Wolfgang
    Haferlach, Torsten
    Haferlach, Claudia
    BLOOD, 2023, 142
  • [10] Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes
    Aguirre, Luis E.
    Al Ali, Najla
    Ball, Somedeb
    Singh, Avani M.
    Jain, Akriti G.
    Chan, Onyee
    Schwabkey, Zaker, I
    Tinsley-Vance, Sara M.
    Kuykendall, Andrew
    Sweet, Kendra
    Lancet, Jeffrey E.
    Padron, Eric
    Sallman, David A.
    Komrokji, Rami S.
    BLOOD, 2022, 140 : 1125 - 1127
12345